Dementia represents a major global health challenge, particularly in low- and middle-income countries (LMICs). Morocco, facing rapid population ageing, lacks integrated epidemiological and translational research on Alzheimer's disease (AD) and related disorders.
Objective
This study aims to map Moroccan dementia studies and identify national advances and research gaps.
Methods
Following PRISMA-ScR guidelines, a literature search was conducted in PubMed, Scopus, MEDLINE, and Web of Science covering the period 2000–2025. Studies including Moroccan samples and addressing dementia or AD in epidemiology, diagnostics, genetics, or therapy were retained. Thirty papers met criteria. Data were summarized narratively and organized in four thematic tables.
Results
Moroccan research spans four main pillars: (1) early-onset and clinical features; (2) validated cognitive assessment tools adapted to Arabic and Tamazight; (3) discovery of distinct APP, PSEN, and APOE mutations; and (4) emerging pharmacological and non-pharmacological interventions.
Conclusions
Though still limited, Moroccan dementia research demonstrates scientific maturity and regional relevance. Establishing national registries, biobanks, and culturally tailored interventions will strengthen Africa's contribution to global neurodegenerative research.
HackerK. The burden of chronic disease. Mayo Clin Proc Innov Qual Outcomes2024; 8: 112–119.
3.
BabulalGMZhaWTraniJF, et al.Identifying gaps and barriers in Alzheimer’s disease and related dementia research and management in low- and middle-income countries: a survey of health professionals and researchers. J Alzheimers Dis2024; 101: 1307–1320.
4.
MziwiraMAhajiANaciriK, et al.Socio-economic characteristics, health status and access to health care in an elderly Moroccan community: study of the gender factor. Rocz Panstw Zakl Hig / Ann Natl Inst Hyg2022; 73: 341–349.
5.
KhatibNEl HarchILamkaddemA, et al.The Moroccan MoCA test: translation, cultural adaptation, and validation. Appl Neuropsychol Adult2024; 31: 1256–1260.
6.
OugjijAAAchbaniAChigrF. Cross-cultural adaptation and psychometric validation of the Moroccan dialect version of the zarit scale of dementia Caregivers’ burden. Electron J Gen Med2022; 19: em374.
7.
TriccoACLillieEZarinW, et al.PRISMA Extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med2018; 169: 467–473.
8.
KhattabHHabtanyYFerdousB, et al.Démences dégénératives juvéniles : profil épidémiologique et étiologique au CHU de Casablanca sur dix ans. Ann Méd Psychol2020; 178: 373–377.
9.
OuanoucheEHLamineHTlijiA, et al.Epidemiological profile of psychiatric illnesses in the province of Taza, Morocco: case of a study on a schizophrenic sub-population in the Ibn Baja hospital. Egypt J Neurol Psychiatry Neurosurg2021; 57: 64.
10.
El KadmiriNEl MoutawakilBSlassiI, et al.Clinical and genetic aspects of Moroccan patients with Alzheimer’s disease. J Neurol Sci2013; 333: e323.
11.
AzdadABenabdeljlilMFarisMEA. Comparison of metrological qualities of the Moroccan versions of MMSE (MMSE-MA) and MOCA (MOCA-MA) for detecting mild cognitive impairment and Alzheimer’s disease in Moroccan population. J Neurol Sci2023; 455: 82.
12.
AzdadABenabdeljlilMFarisMEA. Validation of the free and cued selective reminding test in Moroccan patients with mild cognitive impairment or Alzheimer’s disease. J Neurol Sci2023; 455: 81.
13.
FeketeMVargaPUngvariZ, et al.The role of the Mediterranean diet in reducing the risk of cognitive impairement, dementia, and Alzheimer’s disease: a meta-analysis. GeroScience2025; 47: 3111–3130.
14.
El KadmiriNZaidNZaidY, et al.Novel presenilin mutations within Moroccan patients with early-onset Alzheimer’s disease. Neuroscience2014; 269: 215–222.
15.
El KadmiriNZaidNHachemA, et al.Novel mutations in the amyloid precursor protein gene within Moroccan patients with Alzheimer’s disease. J Mol Neurosci2014; 53: 189–195.
16.
Kadmiri NECuardosREl MoutawakilB, et al.A proteomic approach for the involvement of the GAPDH in Alzheimer disease in the blood of Moroccan FAD cases. J Mol Neurosci2014; 54: 774–779.
17.
Ben HallaSTazziteAGazzazB, et al.The impact of ABCB1 gene polymorphism (C3435T) and its expression on response to donepezil in Moroccan patients with Alzheimer’s disease. Gene Reports2022; 26: 101443.
18.
HallaSBTazziteAGazzazB, et al.Involvement of APOE polymorphism in Alzheimer’s disease susceptibility and donepezil response in Moroccan patients. Gene Reports2022; 26: 101484.
19.
RazouqiYEl BouchikhiIEl-AbidH, et al.Novel APOE mutation in a Moroccan subject suffering from Alzheimer disease: a case study and exploration of pathogenic implication. Alzheimer Dis Assoc Disord2023; 37: 370–372.
20.
GuerguerFZBouribabAKarimEM, et al.Moroccan Natural products for multitarget-based treatment of Alzheimer’s disease: a computational study. PLoS One2025; 20: e0313411.
21.
ChennaiHYBelaidiSBourougaaL, et al.Identification of potent acetylcholinesterase inhibitors as new candidates for Alzheimer disease via virtual screening, molecular docking, dynamic simulation, and molecular mechanics–Poisson–Boltzmann surface area calculations. Molecules2024; 29: 1232.
22.
GuerguerFZRossafiBAbchirO, et al.Potential Azo-8-hydroxyquinoline derivatives as multi-target lead candidates for Alzheimer’s disease: an in-depth in silico study of monoamine oxidase and cholinesterase inhibitors. PLoS One2025; 20: e0317261.
23.
NourHAbchirOMounadiN, et al.Exploration of natural products for the development of promising cholinesterase inhibitors in Alzheimer’s disease treatment. Heliyon2025; 11: e42479.
24.
El AlloucheYAlaqarbehMEl AissouqA, et al.Chemoinformatics study of benzodiazepine-1, 2, 3-triazole derivatives targeting butyrylcholinesterase. J Fluoresc2025; 35: 3667–3680.
25.
AbbaouiZMerzoukiMOualdiI, et al.Alzheimer’s disease: in silico study of rosemary diterpenes activities. Curr Res Toxicol2024; 6: 100159.
26.
GuerguerFZKhedraouiMSamadiA, et al.Computational approaches for multitarget drug design in Alzheimer’s disease: a comprehensive review. Curr Med Chem2025; 32: 7017–7044.
27.
DoumarHEl MostafiHElhessniA, et al.Comparative study of injected Alzheimer’s disease models in rats: insights from experimental research. Pathophysiology2024; 31: 643–659.
28.
BenabdeljlilMAzdadATaiebineM, et al.Non-pharmacological therapy of Alzheimer’s disease in Morocco. Experience of the Alzheimer day center of Rabat. J Neurol Sci2021; 429: 119048.
29.
RedouaneR. Linguistic diversity or linguistic rivalry in Morocco? Realities and perspectives. Int J Educ Hum Dev2016; 2: 18–24.
30.
SolimanAAKhouchaniMRenneEP. Sociocultural barriers related to late-stage presentation of breast cancer in Morocco. J Cancer Educ2019; 34: 735–742.
31.
HendriksSPeetoomKBakkerC, et al.Global prevalence of young-onset dementia: a systematic review and meta-analysis. JAMA Neurol2021; 78: 1080–1090.
32.
SellamiLBen DjebaraMBelhouaneI, et al.P2-100: early-onset versus late-onset Alzheimer’s disease in Tunisia. Alzheimers Dement2015; 11: P522.
33.
HaithemHOnsASalmaN, et al.Association between dementia and vascular disease-associated polymorphisms in a Tunisian population. Int J Neurosci2018; 128: 32–41.
34.
El TallawyHNAFarghalyWMAEl HamedMA, et al.Prevalence of Alzheimer dementia in upper Egypt (Desert areas). Egypt J Neurol Psychiatry Neurosurg2019; 55: 29.
35.
BelhassanKOuldimKSefianiAA. Genetics and genomic medicine in Morocco: the present hope can make the future bright. Mol Genet Genomic Med2016; 4: 588–598.
36.
ZhangX-XTianYWangZ-T, et al.The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis2021; 8: 313–321.
37.
HatabAASamKGBeshirSA, et al.Association of level of adherence to Mediterranean diet with cognitive and dementia status in subjects with chronic diseases: a cross-sectional study. Nutr Neurosci2024; 27: 1123–1130.
38.
Ul RehmanSMitraU. Cognitive handwriting insights for Alzheimer’s diagnosis: a hybrid framework. Inf2025; 16: 1–27.
39.
GroechelRCTripodisYAloscoML, et al.Biomarkers of Alzheimer’s disease in black and/or African American Alzheimer’s disease neuroimaging initiative (ADNI) participants. Neurobiol Aging2023; 131: 144–152.
40.
HajriMAbidliZRamiY, et al.Neurocognitive profile of patients with Alzheimer’s disease: a study in the Moroccan context. Acta Neuropsychol2025; 23: 199–208.
41.
ChangYHawkinsBADuJJ, et al.A guide to in silico drug design. Pharmaceutics2022; 15: 49.
42.
Moradi KashkooliFSoltaniMSouriM, et al.Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine. Nano Today2021; 36: 101057.
43.
World Health Organization. Global action plan on the public health response to dementia 2017–2025. Geneva: World Health Organization, 2017.
44.
EgbeCOBrooke-SumnerCKathreeT, et al.Psychiatric stigma and discrimination in South Africa: perspectives from key stakeholders. BMC Psychiatry2014; 14: 1–14.
45.
AtewologunFAdigunOAOkesanyaOJ, et al.A comprehensive review of mental health services across selected countries in sub-Saharan Africa: assessing progress, challenges, and future direction. Discov Ment Heal2025; 5: 49.
46.
TalhaouiAAboussalehYBikriS, et al.The relationship between adherence to a Mediterranean diet and cognitive impairment among the elderly in Morocco. Acta Neuropsychol2023; 21: 125–138.
47.
ZakiAHindNAderrazzakO. Démence chez un adulte jeune: importance du diagnostic différentiel. À propos d’un cas. Inf Psychiatr2021; 97: 323–327.
48.
RamiYDiounySKissaniN, et al.Cross-cultural adaptation of the Moroccan version of the Mini-mental state examination: a preliminary study. Appl Neuropsychol Adult2024; 31: 595–600.
49.
GhitaAIbtissameAAlaeA, et al.Characteristics of arabic handwriting on graphic tablet in neurodegenerative disease: preliminary results between patients with Alzheimer’s disease and healthy controls. Acta Neuropsychol2022; 20: 53–65.
50.
AsriFMoussaouiDKadriN. Autosomal dominant Alzheimer’s disease. Study of a Moroccan family. Encephale2003; 29: 254–258.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
